bortezomib + fluorouracil + leucovorin + oxaliplatin

This is a combination chemotherapy regimen consisting of four agents: bortezomib, fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Bortezomib is a reversible inhibitor of the 26S proteasome, leading to disruption of protein degradation and induction of apoptosis in cancer cells. Fluorouracil is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. Leucovorin enhances the binding of fluorouracil to thymidylate synthase, increasing its cytotoxicity. Oxaliplatin is a platinum-based chemotherapeutic that forms DNA crosslinks and induces apoptosis. This combination has been investigated primarily for advanced or metastatic colorectal cancer, with early-phase studies showing partial responses and stable disease in some patients[1][2][8]. The regimen leverages synergistic mechanisms to enhance anti-tumor activity.